HHS Nominates 2 Acting Officials to Top FDA Drug and Biologics Posts
Updated
Updated · The Washington Post · Sep 8
HHS Nominates 2 Acting Officials to Top FDA Drug and Biologics Posts
3 articles · Updated · The Washington Post · Sep 8
Summary
HHS formally put Michael Davis forward to become the FDA’s top drug regulator and Karim Mikhail to lead the agency’s biologics office, converting both from acting leaders to nominees.
The move fills two of the FDA’s most senior product-review roles and comes as the department also advances other leadership picks across HHS.
Next Tuesday, the Senate Finance Committee is set to hold a confirmation hearing for Chris Klomp as HHS deputy secretary and Ge Bai as an HHS assistant secretary.
The nominations land as FDA is juggling broader policy work, including a new push to gather industry input on how to speed development of plant-derived prescription drugs.